Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 10:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,749 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Platinum-based Chemotherapy Clear all
Recruiting Phase 3 Interventional

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

NCT06627647
View directory record Official record
Conditions
Non-squamous Non-small Cell Lung Cancer
Interventions
Rilvegostomig, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
78
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 6, 2026, 10:22 AM EDT
Terminated Phase 3 Interventional

Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer

NCT00237575
View directory record Official record
Conditions
Bladder Cancer
Interventions
gemcitabine, cisplatin, sargramostim, filgrastim
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
4
States / cities
Louisville, Kentucky • Omaha, Nebraska • Hawthorne, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Oct 6, 2026, 10:22 AM EDT
Active, not recruiting Phase 2 Interventional

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

NCT00869232
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Velcade, Melphalan, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma

NCT04205630
View directory record Official record
Conditions
Endometrial Cancer
Interventions
SYD985
Drug
Lead sponsor
Byondis B.V.
Industry
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Phase 1 Interventional

AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers

NCT00678132
View directory record Official record
Conditions
Neoplasms
Interventions
AZD 2281, Cisplatin, Gemcitabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

NCT01982448
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Cisplatin, Paclitaxel
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
20
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Baltimore, Maryland + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Phase 1Phase 2 Interventional

Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer

NCT00101842
View directory record Official record
Conditions
Carcinoma, Transitional Cell
Interventions
Pemetrexed, Gemcitabine, Platinol
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2006 · Synced Oct 6, 2026, 10:22 AM EDT
Recruiting Phase 2 Interventional

Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer

NCT07402473
View directory record Official record
Conditions
HER2-positive Early-stage Breast Cancer
Interventions
Trastuzumab, Pertuzumab, Docetaxel, Carboplatin
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Elizabeth, New Jersey • Hamilton, New Jersey • Long Branch, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Phase 1 Interventional

CIML NK Cell in Head & Neck Cancer

NCT04290546
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Interleukin-15 Superagonist (N-803), CIML NK cell Infusion, Ipilimumab, Cetuximab
Drug · Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

NCT03358472
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Pembrolizumab, Epacadostat, Cetuximab, Cisplatin, Carboplatin, 5-Fluorouracil
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
14
States / cities
Anaheim, California • Sacramento, California • Santa Rosa, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Phase 1 Interventional

Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck

NCT00513383
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Panitumumab, Carboplatin, Paclitaxel, Intensity Modulated Radiation Therapy, 5-Fluorouracil, Docetaxel, Cisplatin
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

NCT03675737
View directory record Official record
Conditions
Stomach Neoplasms
Interventions
Pembrolizumab, Cisplatin, 5-fluorouracil, oxaliplatin, capecitabine, Placebo for Pembrolizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy

NCT00318370
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Interventions
Farletuzumab, Chemo Plus Far
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
18
States / cities
San Diego, California • Indianapolis, Indiana • Covington, Louisiana + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2015 · Synced Oct 6, 2026, 10:22 AM EDT
Not listed Phase 2 Interventional

Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse

NCT00069966
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, cisplatin, cytarabine, methylprednisolone, pixantrone dimaleate, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Theradex
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
28
States / cities
Tucson, Arizona • Duarte, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2009 · Synced Oct 6, 2026, 10:22 AM EDT
Recruiting Phase 1 Interventional

9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

NCT06896188
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Retifanlimab, Chemotherapy, 9-ING-41
Drug
Lead sponsor
Anwaar Saeed
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer

NCT01938573
View directory record Official record
Conditions
Recurrent Bladder Carcinoma, Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer
Interventions
Cisplatin, Gemcitabine Hydrochloride, Sirolimus, Cystectomy
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)

NCT01820754
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Ipilimumab, Paclitaxel, Cisplatin, Carboplatin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer

NCT02659059
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer
Interventions
Nivolumab, Ipilimumab, Platinum Doublet Chemotherapy
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
29
States / cities
San Diego, California • Plainville, Connecticut • Weston, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 6, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

CISPLATIN + AZD-1775 In Breast Cancer

NCT03012477
View directory record Official record
Conditions
Triple-negative Metastatic Breast Cancer
Interventions
Cisplatin, AZD1775
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 6, 2026, 10:22 AM EDT
Terminated No phase listed Observational

Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy

NCT04676386
View directory record Official record
Conditions
NSCLC Stage IV, NSCLC, Stage IIIC
Interventions
Primary Immune Response (PIR) test by Biodesix, Inc.
Diagnostic Test
Lead sponsor
Addario Lung Cancer Medical Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
San Carlos, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 6, 2026, 10:22 AM EDT
Terminated Phase 2 Interventional Results available

Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation

NCT01151761
View directory record Official record
Conditions
Cholangiocarcinoma, Hepatobiliary Neoplasm, Liver Cancer, Bile Duct Cancer, Cancer of Gallbladder
Interventions
Stereotactic Body Radiotherapy, Gemcitabine, Cisplatin, Carboplatin, Capecitabine, 5FU, Liver transplantation
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 6, 2026, 10:22 AM EDT
Active, not recruiting Phase 2 Interventional

Afatinib With CT and RT for EGFR-Mutant NSCLC

NCT01553942
View directory record Official record
Conditions
Lung Cancer
Interventions
Afatinib, Radiation, Cisplatin, Pemetrexed, Surgery
Drug · Radiation · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 6, 2026, 10:22 AM EDT
Not listed Phase 3 Interventional

Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors

NCT00392886
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carboplatin, cisplatin, cyclophosphamide, etoposide, methotrexate, temozolomide, thiotepa, vincristine sulfate, autologous bone marrow transplantation, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 10 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
29
States / cities
Phoenix, Arizona • Loma Linda, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 6, 2026, 10:22 AM EDT
Withdrawn No phase listed Observational

Cost Utility Analysis in Recurrent Ovarian Cancer

NCT00813254
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Oct 6, 2026, 10:22 AM EDT